INS and Hypoglycemia: The literature mentions that tirzepatide can cause mild to moderate hypoglycaemia as an adverse effect; however, the overall pattern suggests that it has a low risk of significant symptomatic hypoglycaemia, especially if not combined with insulin or sulfonylureas [70].